PHARMACOTHERAPY FOR INFLAMMATORY DISEASES OF THE LUNG WITH DORNASEALPHA


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Mucolytics are extensively used in the treatment of various lung diseases with impaired mucociliary clearance and mucus hyperproduction. The role of recombinant human DNAase (rhDNAase, Pulmozyme) in the treatment of children and adults with lung disease not caused by cystic fibrosis has not been well established. The paper reviews the available reports on the results of clinical trials evaluating rhDNAase.

About the authors

T Gembitskaya

Email: mukoviscidoz otd@mail.ru

A Chermenskiy

Email: mukoviscidoz otd@mail.ru

T Gembitskaya

Research Institute of Pulmonology Academician LP. Pavlov Saint PetersburgMedical University

; Research Institute of Pulmonology Academician LP. Pavlov Saint PetersburgMedical University

A Chermensky

Research Institute of Pulmonology Academician LP. Pavlov Saint PetersburgMedical University

; Research Institute of Pulmonology Academician LP. Pavlov Saint PetersburgMedical University

References

  1. Волков И.К. Возможности использования дорназы альфа (Пульмозим) в детской пульмонологии // Пульмонология. - 2004; 4: 113-117.
  2. Симанова Т.В., Ожегов A.M. Эффективность препарата Дорназа альфа у детей и подростков с хроническими воспалительными заболеваниями легких // Consilium medicum; 2008; приложение «Болезни органов дыхания»: 50-53.
  3. Berge M., Brinkhorst G., Kroon A.A., de Jongste J.С. Dnase treatment in primary ciliary dyskinesia - Assessment by nocturnal pulse oximetry // Pediatr. Pulmonol.-1999; 27: 59-61.
  4. Boeuf В., Prouix F., Morneau S. et al. Safety of endotracheal rhDNAse (Pulmozyme) for treatment of pulmonary atelectasis in mechanically ventilated children // Pediatr. Pulmonol. - 1998; 26:147.
  5. Boogaard R., Hulsmann A.R., van Veen L. et al. Recombinant human deoxyribonuclease in infants with respiratory syncytial virus bronchiolitis // Chest.-2007;131:788-795.
  6. Desai M.,Weller P.H..Spencer D.A. Clinical benefit from nebulized human recombinant DNase in Kartagener's syndrome // Pediatr. Pulmonol. - 1995; 20: 307-308.
  7. Durward A., Forte V., Shemie S.D. Resolution of mucus plugging and atelectasis after intratracheal rhDNase therapy in a mechanically ventilated child with refractory status asthmaticus // Crit. Care Med. - 2000; 28: 560-562.
  8. Hendriks Т., de Hoog M., Lequin M.H. et al. DNase and atelectasis in non-cystic fibrosis pediatric patients // Crit. Care. - 2005; 9: 351-356.
  9. Kupeli S., Teksam O., Dogru D. et al. Use of recombinant human DNase in a premature infant with recurrent atelectasis // Pediatr. Int. -2003;45:584-586.
  10. Merkus P.J., de Hoog M., van Gent R. et al. DNase treatment for atelectasis in infants with severe respiratory syncytial virus bronchiolitis // Eur. Respir. J.-2001; 18: 734-737.
  11. Nasr S.Z., Strouse P.J., Soskolne E. et al. Efficacy of recombinant human deoxyribonuclease lin the hospital management of respiratory syncytialvirus bronchiolitis // Chest. - 2001; 120: 203-208.
  12. Patel A., Harrison E., Durward A. et al. Intratracheal recombinant human deoxyribonuclease in acute life-threatening asthma refractory to conventional treatment// Br. J. Anaesth. - 2000; 84: 505-507.
  13. Reiter P.D., Townsend S.F., Velasquez R. Dornase alfa in premature infants with severe respiratory distress and early bronchopulmonary dysplasia //J. Perinatal. - 2000; 20: 530-534.
  14. Riethmueller J., Borth-Bruhns Т., Kumpf M. et al. Recombinant human deoxyribonuclease shortens ventilation time in young, mechanically ventilated children // Pediatr. Pulmonol. - 2006; 41: 61-66.
  15. Rogers D.F. Mucoactive drugs for asthma & COPD: any place in therapy? // Expert. Opin. Invest. Drugs. - 2002; 11:15-35.
  16. Simpson G., Roomes D., Reeves B. Succeful treatment of empyema thoracis with human recombinant deoxyribonuclease // Thorax. - 2003; 58: 363-366.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Russkiy Vrach Publishing House